
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
FDA removes partial hold on Telcyta clinical development
FDA removes partial hold on Telcyta clinical development
PALO ALTO, CaliforniaTelik, Inc. has announced that the FDA has removed the partial hold on Telcyta (canfosfamide HCl) clinical trials. This action follows a complete review of Telcyta data by the agency and permits the resumption of Telcyta clinical development. Telcyta is a tumor-activated small-molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small-cell lung cancer. FDA placed the hold on development after phase III data showed lower median survival for women with advanced ovarian cancer receiving Telcyta vs standard chemotherapy.
Articles in this issue
almost 18 years ago
MT103, BiTE antibody, enters phase II testing for ALLalmost 18 years ago
Sides dig in as ESA policy debate heats upalmost 18 years ago
Ixempra gets ok for resistant breast canceralmost 18 years ago
ASCO adds Oncotype DX to marker guidelinealmost 18 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenalmost 18 years ago
Accelerated approval for Tasignaalmost 18 years ago
Oxidative stress inducer ups survival in advanced melanomaalmost 18 years ago
Should all HER2+ pts receive adjuvant trastuzumab?almost 18 years ago
R-CHOP is standard of care for advanced DLBCL patientsalmost 18 years ago
FDA oks Velcade for patients with renal dysfunctionNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.